1. Home
  2. STBA vs ARDX Comparison

STBA vs ARDX Comparison

Compare STBA & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo S&T Bancorp Inc.

STBA

S&T Bancorp Inc.

HOLD

Current Price

$43.12

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$5.90

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STBA
ARDX
Founded
1902
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
STBA
ARDX
Price
$43.12
$5.90
Analyst Decision
Hold
Strong Buy
Analyst Count
6
7
Target Price
$43.00
$15.14
AVG Volume (30 Days)
162.1K
3.0M
Earning Date
04-23-2026
04-30-2026
Dividend Yield
3.31%
N/A
EPS Growth
2.35
N/A
EPS
3.49
N/A
Revenue
N/A
$2,607,000.00
Revenue This Year
$10.20
$37.75
Revenue Next Year
$4.14
$34.24
P/E Ratio
$12.46
N/A
Revenue Growth
N/A
N/A
52 Week Low
$34.01
$3.50
52 Week High
$44.91
$8.40

Technical Indicators

Market Signals
Indicator
STBA
ARDX
Relative Strength Index (RSI) 52.00 45.34
Support Level $42.08 $5.49
Resistance Level $43.42 $6.23
Average True Range (ATR) 0.91 0.24
MACD -0.07 -0.01
Stochastic Oscillator 29.04 25.31

Price Performance

Historical Comparison
STBA
ARDX

About STBA S&T Bancorp Inc.

S&T Bancorp Inc is a bank holding company. The company operates in five markets including Western Pennsylvania, Eastern Pennsylvania, Northeast Ohio, Central Ohio and Upstate New York. The company provides financial services with retail and commercial banking products, cash management services, trust and brokerage services. It operates only in one segment which is Community Banking. The company earns revenue from interest on loans and securities and fees charged for financial services provided to its customers.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: